Comprehensive Analysis of MICALL2 Reveals Its Potential Roles in EGFR Stabilization and Ovarian Cancer Cell Invasion

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Molecules interacting with CasL (MICALs) regulate cell motility through cytoskeleton rearrangement.
• The precise mechanisms governing cancer cell invasion, particularly in ovarian cancer, require further elucidation.
• MICALL2, a member of the MICAL family, is investigated for its role in ovarian cancer progression.

Purpose of the Study:

• To investigate the role of MICALL2 in ovarian cancer cell invasion and function.
• To explore the molecular mechanisms by which MICALL2 influences tumor progression and immune responses.

Main Methods:

• Bioinformatic analysis of patient data to correlate MICALL2 expression with clinical outcomes and immune markers.
• In vitro experiments assessing MICALL2's impact on invadopodium formation, cell invasion, and signaling pathways (EGFR-AKT-mTOR, Rac1).
• Gene silencing and pharmacological inhibition (autophagy inhibitors) to dissect molecular interactions.

Main Results:

• MICALL2 expression is elevated in advanced ovarian cancer, correlating with poor survival and increased immune cell infiltration.
• MICALL2 promotes ovarian cancer cell invasion by upregulating MMP9 expression and facilitating invadopodium formation.
• MICALL2 prevents EGFR degradation in a Rac1-dependent manner, activating the EGFR-AKT-mTOR-MMP9 signaling cascade.

Conclusions:

• MICALL2 plays a significant role in ovarian cancer progression, contributing to immune infiltration and invasion.
• MICALL2's mechanism involves Rac1-mediated inhibition of EGFR degradation, leading to downstream signaling activation and matrix degradation.
• Targeting MICALL2 may offer a therapeutic strategy for ovarian cancer by inhibiting invasion and modulating the tumor microenvironment.